Oral GLP-1 Pills vs Injections: What the Trial Evidence Shows

For years, "GLP-1" meant a weekly injection. That's no longer the whole story. Oral formulations are now real, FDA-approved options with their own trial data — not just a promise on a roadmap. Here's how the pill evidence actually stacks up against the injections it's competing with.

The new approval: Foundayo (orforglipron)

Foundayo, the oral brand name for orforglipron, received its initial U.S. approval in 2026 for weight management in adults with obesity or overweight with a weight-related condition, taken once daily rather than once weekly¹. Unlike oral semaglutide, orforglipron is a small-molecule GLP-1 receptor agonist — it isn't a peptide, which is part of why it can be manufactured and absorbed as a standard tablet without the special coating and dosing restrictions oral semaglutide requires².

In the ATTAIN-1 phase 3 trial, orforglipron produced dose-dependent weight loss at 72 weeks: -7.5% at 6 mg, -8.4% at 12 mg, and -11.2% at the highest 36 mg dose, versus -2.1% on placebo². At the top dose, 54.6% of participants lost at least 10% of body weight, and 18.4% lost at least 20%². Discontinuation due to adverse events ran from 5.3% to 10.3% across orforglipron dose groups, versus 2.7% on placebo, with gastrointestinal effects — described in the trial as mostly mild to moderate — as the dominant reason².

Oral semaglutide: the OASIS trials

Semaglutide's oral pathway is older and better established. The OASIS 1 trial tested a 50 mg oral semaglutide tablet against placebo over 68 weeks in adults with overweight or obesity without diabetes: mean weight change was -15.1% on oral semaglutide versus -2.4% on placebo, with 85% of the treatment group losing at least 5% of body weight compared with 26% on placebo³. Gastrointestinal adverse events were reported in 80% of the oral semaglutide group versus 46% on placebo³ — a materially higher GI rate than the injectable Wegovy trial reported for nausea alone, underscoring that "oral" doesn't automatically mean "gentler."

How the pills compare to the injections

Set next to the injectable pivotal trials, the picture is nuanced rather than a clean pill-beats-injection or injection-beats-pill story. Injectable semaglutide (Wegovy) produced roughly 15% average weight loss in STEP 1⁴, almost identical to oral semaglutide's -15.1% in OASIS 1³ — the molecule performs similarly regardless of route once you're at an effective dose. Injectable tirzepatide (Zepbound) remains the highest-efficacy option in head-to-head terms, with SURMOUNT-1 reporting weight loss up to roughly 21% at its top dose⁵; orforglipron's 72-week ATTAIN-1 results (up to -11.2%) sit below both semaglutide routes. This is an evolving, actively researched area — Eli Lilly's ATTAIN program includes maintenance and combination studies that continue to report new data, so treat any single trial snapshot as a point-in-time result rather than a final verdict. For the injectable side-effect data these numbers sit against, see GLP-1 side effects: what the STEP and SURMOUNT trials actually reported.

The oral evidence base is still expanding

ATTAIN-1 isn't the only orforglipron trial reporting results. ATTAIN-2 tested the same drug in adults with obesity who also have type 2 diabetes⁶, and ATTAIN-MAINTAIN — a phase 3b trial — specifically tested whether orforglipron sustains weight loss over an extended maintenance period rather than just producing it initially⁷. That's worth knowing if you're evaluating a newly approved drug: the FDA's 2026 approval didn't rest on a single trial, and the evidence base for how orforglipron performs in different populations and over longer timeframes continues to grow. The same is true on the semaglutide side, where oral and injectable formulations continue to be studied for how they compare directly rather than just against placebo.

The molecule matters more than "oral vs injectable" as a label

It's tempting to treat "oral" as a single category, but the OASIS 1 and ATTAIN-1 numbers above show that's misleading — two oral GLP-1s from different drug classes produced meaningfully different weight-loss and GI results. Oral semaglutide is a peptide requiring an absorption-enhancing formulation and a strict empty-stomach dosing window; orforglipron is a small molecule without those constraints. The route (pill vs. injection) is one variable; the underlying molecule and mechanism is a separate, often more important one. Don't assume every current or future oral GLP-1 will perform like the two covered here.

Why the route matters beyond the number on the scale

An oral pill removes the needle, which matters enormously to some people regardless of the efficacy gap. It also changes the dosing habit — Foundayo is once daily, existing injections are once weekly — which is a real behavioral trade-off, not just a preference. And a pill formulation changes how gastric-emptying drug interactions play out, which is covered in GLP-1 drug interactions: what to tell your prescriber. None of this makes one route objectively "better" — it makes route a real variable to discuss with your prescriber alongside efficacy.

Pricing an oral option

Cash-pay pricing for newly approved oral GLP-1s is still settling, and it's a different landscape from the compounded-injectable market most of our semaglutide and tirzepatide boards track. See our cheapest GLP-1 pill board for how programs currently price oral options, and check which formulations each provider actually offers in our provider reviews before assuming a program's advertised drug is the one you'll be prescribed.

This piece sits in our research index alongside every other sourced explainer we publish — the trials, the compounding rules and the pricing mechanics, grouped by the question each one answers.